Kalytera Announces Modification to Sale Period for Shares Issued under Payments Agreement

SAN FRANCISCO, Calif. and TEL AVIV, Israel, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced a modification to the sale period contemplated by the irrevocable selling agreement between Salzman Group and its broker with respect to common shares of Kalytera.A  The shares issued to Salzman Group under the previously announced payments agreement will now be sold by the broker over ten trading days (rather than five trading days).A  Under the payments agreement with the Salzman Group of Israel, Kalytera paid the Salzman Group USD$300,000 (CDN$399,150)A through the issuance of Common Shares of the Company (a??Common Sharesa??) at a deemed issued price of CDN$0.05 per Common Share, for certain services previously provided to the Company by the Salzman Group.
Under various agreements and work orders, the Salzman Group has provided certain services in connection with the Companya??s programs for the development of cannabidiol (a??CBDa??) for the prevention and treatment of graft versus host disease (a??GVHDa??).About Kalytera Therapeutics
Kalytera Therapeutics, Inc. is pioneering the development of CBD therapeutics. Through its proven leadership, drug development expertise, and intellectual property portfolio, Kalytera seeks to establish a leading position in the development of CBD medicines for a range of important unmet medical needs, with an initial focus on GVHD.

Website Home:A

News and Insights:A


Cautionary StatementsNeither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Апрель 2020    »